Sustained Release of the CCR5 Inhibitors CMPD167 and Maraviroc
from Vaginal Rings in Rhesus Macaques

R. Karl Malcolm,1* Ronald S. Veazey,2 Leslie Geer,3 Deborah Lowry,1 Susan M. Fetherston,1
Diarmuid J. Murphy,1 Peter Boyd,1 Ian Major,1 Robin J. Shattock,4 Per Johan Klasse,5 Lara A. Doyle,2
Kelsi K. Rasmussen,2 Laurie Goldman,3 Thomas J. Ketas,5 John P. Moore5

School of Pharmacy, Queen’s University Belfast, Belfast BT9 7BL, UK1; Tulane National Primate
Research Center, Tulane University Health Sciences Center, Covington, LA 70433, USA2; Particle
Sciences, Bethlehem, PA, USA3; Medical School Building, St Mary’s Campus, Imperial College,
London, W21PG4; Department of Microbiology and Immunology, Weill Medical College of Cornell
University, New York, NY 10021, USA5

* Corresponding author / reprints: R. Karl Malcolm, School of Pharmacy, Queen’s University Belfast,
Belfast BT9 7BL, UK. Tel.: +44 (0)28 9097 2319; Fax: +44 (0)28 9024 7794, E-mail:
k.malcolm@qub.ac.uk

Conflicts of Interest: No conflicts of interest are declared for any of the authors.

Sources of support: The work was funded through NIH grant, U19 AI076982. Maraviroc and
CMPD167 were supplied by ViiV Healthcare and the International Partnership for Microbicides,
respectively.

Running Title: Release of CCR5 inhibitors from vaginal rings
Keywords: HIV-1 microbicides; CCR5 Inhibitors; Sustained release vaginal ring; Depo-Provera; Pharmacokinetics; Maraviroc; CMPD167
ABSTRACT

Antiretroviral entry inhibitors are now being considered as vaginally administered microbicide candidates for prevention of sexual transmission of human immunodeficiency virus. Previous studies testing the entry inhibitors maraviroc and CMPD167 in aqueous gel formulations showed efficacy in the macaque challenge model, although protection was highly dependent on the time period between initial gel application and subsequent challenge. In this paper, we describe the sustained release of the entry inhibitors maraviroc and CMPD167 from matrix-type silicone elastomer vaginal rings both in vitro and in vivo. Both inhibitors were released continuously over 28 days from rings in vitro, at rates of 100-2500 µg/day. In 28-day pharmacokinetic studies in rhesus macaques, the compounds were measured in the vaginal fluid and vaginal tissue; steady state fluid concentrations were ~10^6 fold greater than IC_{50} values for SHIV-162P3 inhibition in macaque lymphocytes in vitro. Plasma concentrations for both compounds were very low. Pretreatment of macaques with Depo-Provera® (DP), as commonly used in macaque challenge studies, was shown to significantly modify the bio-distribution of the inhibitors, but not the overall amount released. Vaginal fluid and tissue concentrations were significantly decreased while plasma levels increased with DP pretreatment. These observations have implications for designing macaque challenge experiments, and also for ring performance during the human female menstrual cycle.

Abstract word count: 210
INTRODUCTION

Orally administered antiretroviral drugs (ARVs) are now important for reducing viral loads in HIV-infected individuals and preventing the worldwide spread of HIV-1 infection (6, 14). The vaginal application of ARVs as ‘microbicides’ has also emerged as a key prevention strategy in protecting women against infection (7, 23, 36, 41, 44). It is now widely acknowledged that microbicides should be based on ARVs similar to those used for treatment, for reasons of potency and practicality (13, 20, 21). The positive outcome of the CAPRISA trial of the reverse transcriptase inhibitor (RTI) tenofovir formally validates the concept of ARV-based microbicides (17, 18).

In addition to RTIs, other classes of ARVs are also worth evaluating as microbicides, in part to counter the increased spread of RTI-resistant viruses resulting from expanded treatment programs with same drug class (42). Using more than one ARV class in a co-formulated microbicide could also increase both the potency and breadth of protection (15, 34). Small molecule CCR5 inhibitors represent one such class, exemplified by the licensed drug maraviroc (MVC), which binds the CCR5 co-receptor and prevents cell entry of the most frequently transmitted HIV-1 strains (24, 29, 35). Both MVC and another CCR5 inhibitor, CMPD167, have already been shown to prevent vaginal transmission of SHIV-162P3 to macaques when delivered vaginally in an aqueous gel formulation (46, 47).

A microbicide product must be delivered in a way that maximises its usage. In the CAPRISA trial, aqueous gel-formulated tenofovir provided ~50% protection when applied at or around the time of intercourse (17). The incomplete protection observed resulted from limited adherence to the relatively complex BAT24 dosing regime, in which a single vaginal gel dose was applied within 12 h before sex followed by a second dose up to 12 h after sex, irrespective of the number of sex acts within that period (17,18). A better strategy, particularly for women at high risk of infection, would be a microbicide
administered independently of coitus (e.g., a once-daily gel), and that maintained protective ARV concentrations between applications. We have shown that MVC can be formulated in a non-aqueous, silicone-based gel that sustains high concentrations in the macaque vagina for up to 24 h (11).

Vaginal rings represent an alternative delivery method for providing sustained drug release into the vaginal lumen and tissue (26). A matrix-type vaginal ring releasing the RTI dapivirine continuously for 28 days is presently in clinical development and due to enter Phase III testing in 2012 (26, 31). Here, we show that both MVC and CMPD167 can be formulated in similar vaginal ring devices, and released both in vitro and in rhesus macaques. We also explored whether pre-treatment of the macaques with Depo-Provera® (DP) influences release in vivo. DP is commonly used to synchronize the macaque menstrual cycle and thin the vaginal epithelium prior to viral challenge experiments, thereby increasing susceptibility to infection (27, 46, 47). Although DP is known to affect vaginal/cervical histology and physiology (12, 16, 28), it is unclear how relevant these changes are to virus transmission events, and how they influence the pharmacokinetics of vaginal microbicides.
MATERIAL AND METHODS

Water solubility

MVC and CMPD167 were supplied by ViiV Healthcare and the International Partnership for Microbicides, respectively. Water solubilities were determined in quadruplicate using the shake-flask method. Excess compound (~25 mg) was added to 10 mL HPLC-grade water, vortexed (1 min), and placed in an orbital incubator (37°C, 60 rpm; Infors HT Unitron, Switzerland) for 72 h. Samples were stored at room temperature for a further 24 h before filtering (0.2 µm cellulose acetate membrane syringe filter; Minisart®, Sartorius Stedim Biotech, France) and HPLC analysis (Waters 1525 Binary HPLC pump, 717 Plus Autosampler, In-line Degasser AF Unit, 2487 Dual λ Absorbance Detector) with a Luna C18(2) 100, 5 µm column (150 x 4.60 mm) (Phenomenex, UK) at 30°C. For MVC samples, gradient elution involved a mobile phase of 10 mM KH₂PO₄ buffer, pH 3.0 (solvent A) and acetonitrile (solvent B) with a 1.0 mL/min flow rate (0-4 min 70-20% A; 4.0-4.5 min 20-70% A; 4.5-7.0 min 70% A). MVC was detected at 3.3 min (210 nm). For CMPD167, isocratic HPLC was performed with a mobile phase of 0.1% trifluoroacetic acid in water/acetonitrile (70:30), a flow rate of 1.0 mL/min, and detection at 210 nm. The retention time was 6.4 min.

pKa and logP values

Ionisation constants and logP values were measured with a Sirius T3 instrument (Sirius Analytical Instruments, UK). Titrations were performed in 0.15 M KCl under nitrogen at 25°C. Apparent ionisation constants (psKa) were determined in methanol/water mixtures, extrapolating to 0% methanol to give aqueous pKa values (1, 3, 38, 43).

Vaginal ring manufacture
Matrix-type, silicone elastomer, macaque-sized vaginal rings loaded with 400 mg micronised CMPD167 or MVC were manufactured by reaction injection molding. Each CCR5 inhibitor was mixed (1 min, 3000 rpm, SpeedMixer™ DAC 150 FVZ-K; Synergy Devices, UK) into both Parts A and B of silicone elastomer LSR9-9508-30 (Nusil Technology, USA). The active parts were combined (1:1 w/w), speed-mixed (1 min, 3000 rpm), injected into stainless steel molds in a laboratory-scale ring-making machine, and cured (3 min, 80ºC). The rings, weighing 1.85 g ± 0.01 g, measured 25.0 and 6.0 mm in external and cross-sectional diameters, respectively. Similar control rings have previously been shown to fit rhesus macaques optimally and caused no irritation (33).

In vitro release testing from vaginal rings

Individual rings were placed into screw-top glass bottles containing either 50 or 25 mL simulated vaginal fluid (SVF) (Days 1-4 and Days 7-28, respectively). SVF mimics the chemical composition of vaginal fluid, including pH and osmolarity matched to normal vaginal fluid (32). The bottles were placed in an orbital shaking incubator (37ºC, 60 rpm; throw 25 mm), and the release medium sampled (5 mL) regularly over the 28 day study period. The release medium was completely replaced with fresh warmed medium after each sampling timepoint. The samples were then quantified for MVC or CMPD167 concentration using HPLC, as above, and daily release versus time profiles plotted.

Macaque pharmacokinetic studies

Twenty-four female cycling rhesus macaques (4-14 yr) were housed at Tulane National Primate Research Center in accordance with recommendations in the Guide for the Care and Use of Laboratory Animals of the NIH. The Tulane University Institutional Animal Care and Use Committee approved research. Twelve macaques were dosed once intramuscularly with 30 mg DP one month before ring placement (45). The other twelve were not treated. Twelve macaques per group (six given DP, six not
treated) were fitted with vaginal rings loaded with 400 mg CMPD167 or MVC. Vaginal fluid and blood were collected immediately before the rings were atraumatically placed in the vagina. Additional vaginal fluid and blood samples were collected after 1, 4, 8 h, and then at 1, 2, 3, 4, 7, 10, 14, 21 and 28 days. Vaginal fluid was sampled by placing a pre-weighed Weck-Cel sponge into the vagina and allowing it to absorb (5 min), before removal and immediate transport to a laboratory for processing. The sponges were re-weighed, to calculate the collected vaginal fluid weight. The sponge tips were removed and placed into Spin-X tubes containing a 40 µm filter separating top and bottom chambers. Extraction buffer (300 µL) containing 0.25 M NaCl, 0.2% sodium azide and protease inhibitors (Calbiochem) were added to the top well and the tubes centrifuged (13,000 g, 15 min). The top chambers were removed and the samples stored (-80°C) prior to MVC or CMPD167 quantification. Blood samples were treated with EDTA before plasma was separated by centrifugation (1000 g, 20 min) and stored (-80°C) prior to analysis. Pinch biopsies were sampled as previously described (11).

Quantification of CMPD167 and MVC in biological samples

Plasma, vaginal fluid and vaginal tissue concentrations of CMPD167 and MVC were quantified by gradient reverse-phase HPLC (Prominence, Shimadzu) coupled to a triple-quadrupole mass spectrometer (API3200, Applied Biosystems). The methods are detailed in the Supplementary Digital Content for this manuscript.

Quantification of vaginal ring CMPD167 and MVC content before and after use

The amounts of CMPD167 and MVC remaining in the rings (extracted drug content, E) after in vitro release testing or use in macaques were quantified by solvent extraction. The initial amounts of inhibitor (measured loading, Lm) in rings from the same production batch, but not used in release studies, were measured similarly to allow calculation of the total amount released from each ring (R) as

\[ R = L_m - E \]

Rings were weighed, cut into sections, and refluxed (2 h) in a mixture comprising 95 mL...
dichloromethane and 5 mL internal standard solution (5 mg/mL norethindrone in methanol). A 10 mL aliquot of extraction solution was evaporated to dryness (Buchi Syncore Polyvap, Oldham, UK), reconstituted in 10 mL methanol, diluted 1:20 in methanol, and assayed by HPLC as described previously for solubility quantification.

**Antiviral activity of CMPD167 and MVC in vitro**

Antiviral activity was assessed using both rhesus macaque and human peripheral blood mononuclear cells (PBMC), as described previously (45).

**Statistical analyses**

Statistical analyses used GraphPad Prism software. Data were analyzed using either one or two-way ANOVA, depending on the number of variables to be compared. Significance was noted when $P<0.05$. 

Downloaded from http://aac.asm.org/ on November 12, 2017 by guest
RESULTS

Antiviral activity of CMPD167 and MVC

Maraviroc and CMPD167 inhibited replication of SHIV-162P3 and SIVmac251 in human and macaque PBMC with EC$_{50}$ values in the range 0.1–10 ng/mL (Table 1). Both compounds were less potent against both viruses in macaque PBMC than human. For MVC, the EC$_{50}$ differential was ~5–10 fold, for CMPD167 it was ~1.5–3 fold. Of the two challenge viruses, SHIV-162P3 was the more sensitive to both inhibitors, by 1.2–7.8 fold depending on the virus and cell type.

Water solubility, pKa and logP values for CMPD167 and MVC

For both compounds, the experimentally determined values for water solubility, acid dissociation constants and octanol/water partition coefficients (logP; presented for each ionisation state of the molecules) are summarised in Table 1. Each CCR5 inhibitor is classified as slightly soluble; they exist in different ionisation states depending on the environmental pH.

For MVC, the conjugate acid species of the basic triazole and tropane groups have pKa values of 3.31 and 7.84, respectively. The neutral form of MVC (i.e., with neither group protonated) exists predominantly above pH 8 and has a logP of 2.55 (i.e., hydrophobic). The mono-protonated form (XH$^+$, Table 1), which will predominate in the normal vaginal pH range for both humans (pH 4-5) (32, 39) and rhesus macaques (pH 6-7) (40), has a logP of -0.32 (i.e., hydrophilic). CMPD167 contains one acidic (pK$_{a}=2.35$) and three basic moieties, two of which provide measurable pK$_{a}$ values of 7.84 and 9.40. At normal vaginal pH, the carboxylic acid species and the basic groups are all ionised. Under these conditions, the CMPD167 molecule contains three ionised species (XH$_2^+$) overall, with a logP value of 0.61.
For comparison, various steroidal drugs in marketed vaginal ring devices (i.e., Estring® - estradiol; Femring® - estradiol-3-acetate; Nuvaring® - etonogestrel and ethinyl estradiol; Progering® - progesterone) are non-ionisable, with logP values >2. All these drugs are efficiently absorbed, as required for their particular clinical indications. At normal vaginal pH, the mono-protonated form of MVC, and more so the highly ionised CMPD167, might be less well absorbed than the non-ionised steroidal drugs.

**Release of CMPD167 and MVC from vaginal rings in vitro**

The vaginal rings released both compounds into SVF continuously over a 28-day period (Figure 1). Typical of matrix-type rings, where the solid drug particles are distributed throughout the entire ring, the daily amounts released decreased with time, in accordance with \( t^{1/2} \) kinetics (cumulative release vs. \( t^{1/2} \) plots were linear; \( r^2 > 0.999 \)). MVC release rates were ~10-fold greater than for CMPD167; thus, after 28 days, 127 mg MVC was released, but only 13 mg CMPD167. This differential may be attributed to differences in the silicone elastomer permeability of the compounds, and/or their solubility in SVF.

**Release of CMPD167 and MVC from vaginal rings in the macaque**

Vaginal fluid, vaginal tissue biopsy samples and plasma concentrations were quantified over 28 days in both DP-treated and untreated macaques (Fig. 2). High concentrations of both CCR5 inhibitors were present in vaginal fluid within 24 h after ring insertion, and changed little during the next 28 days. In both groups of animals, the mean vaginal fluid concentrations were significantly higher (~2-3 fold) for MVC than CMPD167. The vaginal fluid concentrations were ~10^4 to 10^5-fold greater than *in vitro* IC\(_{50}\) values for inhibition of SHIV-162P3 infection of rhesus macaque PBMC (Table 1). Vaginal fluid concentrations at most timepoints were significantly greater (~2-5 fold) in untreated macaques than in those pre-treated with DP.
Vaginal tissue biopsies were sampled infrequently during the dosing period to avoid excessive perturbation to the local environment. The tissue concentrations broadly tracked those in vaginal fluid, but were much lower overall at 1,000-20,000 ng/g (Figures 2B and 2E). The tissue levels of both compounds were significantly greater in untreated animals, with MVC concentrations higher than CMPD167. MVC tissue concentrations declined steadily over time from an early peak. Whether the low tissue level of CMPD167 on day-1, compared to day-7, is a true finding requires confirmation.

By comparison, mean plasma levels of both inhibitors were significantly greater in the DP-treated animals (Figures 2C and 2F). Indeed, in the absence of DP, plasma MVC was below the limit of detection (<0.5 ng/mL) and only minimal concentrations (mean, 0-0.2 ng/mL) of CMPD167 were observed from day-7 onwards. When DP was used, early peaks were observed for both CCR5 inhibitors, but greater for CMPD167 (4.1 ng/mL, 24 h) than MVC (1.4 ng/mL, 8 h). Plasma concentrations of each compound then steadily declined, and were 1.0 ng/mL for CMPD167 on day-14 and undetectable for MVC by day-21. The mean plasma concentrations of CMPD167 and MVC (0.1-5 ng/mL range) in the DP recipients are comparable with their IC$_{50}$ values (Table 1), but at least four orders of magnitude lower than those measured in vaginal fluid.

Concentration ratios for CMPD167 and MVC at representative timepoints summarize the pharmacokinetic data (Table 2). The DP:noDP ratios describe the influence of DP pre-treatment on inhibitor levels in the three biological compartments; the hormone increases plasma levels while reducing vaginal fluid and tissue levels for both compounds. Independently of DP pre-treatment, the compartment ratios (VF:VT, VT:BP and VF:BP where VF = vaginal fluid, VT = vaginal tissue and BP = blood plasma) show that inhibitor concentrations increase according to the trend BP<VT<VF. The VF
levels ranged from 8-108 fold higher than VT, while VT levels were from 302-52,600 times greater than BP.

Residual drug content of rings after release in vitro and in macaques

Residual drug content measurements showed that ~3-fold greater amounts of MVC were delivered to macaques over 28 days compared to CMPD167 (Figure 3). The differential is quantitatively consistent with the better release of MVC from the rings in vitro (Figures 1, 3), and with the pharmacokinetic study results (Figure 2). However, the total mass of each compound lost from the rings was very similar for both DP-treated and untreated macaques (Figure 3). Hence, DP influences the bio-distribution of the compounds after release, rather than release per se. Moreover, the amounts of each compound released over 28 days in vitro and in the macaques are comparable (Figure 3). The in vitro release-testing model using SVF is therefore reasonably predictive of what happens under in vivo conditions.

DISCUSSION

The physicochemical properties of drug molecules are fundamental to understanding their absorption characteristics, irrespective of the administration route. A small molecular volume (approximated by a molecular weight < 500 Da), a non-charged structure (according to pKa values), and a relatively hydrophobic character (defined by logP) are all conducive to increased tissue absorption via passive transport mechanisms. Depending on its mechanism of action, a microbicide needs to be present in sufficient quantities in vaginal fluid and/or nearby tissues. Blood levels should be low, to avoid driving the emergence of resistant variants in infected users and to minimize systemic toxicity. High vaginal fluid and/or tissue levels can only be achieved for a microbicide-loaded vaginal ring if the active compound (i) is effectively released from the ring, (ii) has adequate solubility in vaginal fluid, and (iii)
can partition from the vaginal fluid into the nearby tissue. All three processes are ultimately governed by the compound’s physicochemical properties under the conditions present in the vagina. Here, we measure the relevant physicochemical properties of microbicide candidates, CMPD167 and MVC, and use that information to help interpret pharmacokinetic data.

MVC was more water-soluble than CMPD167 (~1 and ~0.5 mg/mL, respectively; Table 1), which was reflected by the in vitro release data (Figure 1) and macaque vaginal fluid levels (Figure 2A and 2D). However, aqueous solubility is not the only parameter governing in vitro release and vaginal fluid levels. Drugs are normally incorporated into silicone elastomer vaginal rings as solid micronised dispersions. A variable fraction remains in the solid state, acting as a drug micro-reservoir within the matrix to replenish what has been released. Moreover, the drug is almost always present in the non-ionised (neutral) state, since no water is present to induce ionisation. For the drug to be released, however, at least some must dissolve within the hydrophobic elastomer. Consequently, when the ring is inserted, a concentration gradient is established across the interface between its surface and the vaginal fluid. If the volume of the solvated molecule is sufficiently small relative to the pore size of the elastomer matrix, passive diffusion occurs. Accordingly, the silicone elastomer solubility of the drug, its initial loading in the ring, and its molecular volume are all key factors influencing release (25). The molecular size and logP values for the neutral forms of MVC (X) and CMPD167 (XH) are similar (Table 1). Hence, their differential water solubilities may explain why MVC is released better in vitro and in vivo.

MVC and CMPD167 release in vivo yielded vaginal fluid concentrations as high as 830,000 and 180,000 ng/mL, respectively (Figures 2 and 3). Such concentrations are $10^5$-$10^6$ fold greater than the in vitro IC$_{50}$ values against SHIV-162P3 infection of macaque PBMC. The significantly (2-3 fold) higher MVC concentrations are consistent with in vitro release data (Figure 1) and residual drug content data.
The amounts of the inhibitors released from the rings were independent of DP use; hormone treatment appears not to influence release per se but rather the subsequent bio-distribution. Thus, DP pre-treatment reduced the concentrations of both compounds in the vaginal fluid and tissue but, conversely, more reached the plasma, particularly at early timepoints. Presumably, the thinner vaginal epithelium permits increased penetration of compounds from the vaginal lumen into the bloodstream. Nonetheless, blood levels were generally very low, particularly in macaques not given DP. The highest plasma concentrations of CMPD167 (low ng/mL range) were similar to in vitro IC₅₀ values, and broadly comparable to plasma dapivirine levels in human females using matrix rings (31). Whether the transient appearance in the plasma of a low level of a topically delivered compound could drive resistance development systemically in women who are unknowingly HIV-1 infected is uncertain.

MVC and CMPD167 were slightly less active against virus replication in macaque PBMC than human, with CMPD167 marginally the more potent inhibitor (Table 1). ³H-MVC binding assays yielded mean Kₐ values of 1.36 and 0.86 nM for macaque and human CCR5, respectively, although the inhibitor dissociated ~10-fold more quickly from macaque CCR5 (30). The IC₅₀ values for MVC inhibition of chemokine binding to macaque and human CCR5 were 17.5 nM and 7.2 nM (30), for CMPD167 they are 7.5 nM and 4.5 nM (M. Springer, personal communication). Thus, the binding and infection-inhibition assays are consistent; both CCR5 inhibitors interact a little less efficiently with macaque CCR5 than human, with CMPD167 moderately the more active. CCR5 inhibitors could fail to protect macaques, on quantitative grounds, while still being effective in humans under comparable conditions.

Other than by conducting an efficacy trial involving thousands of women, only macaque challenge experiments can address whether vaginal rings can protect against infection. We are presently addressing this issue, by quantifying local drug concentrations at the time of challenge after delivery using both gels and vaginal rings. However, the sustained presence of a CCR5 inhibitor such as MVC,
as provided by a vaginal ring, may be beneficial in a way that is not mimicked by a gel. When oral CCR5 inhibitors are given transiently to HIV-1-infected people, the unusually long delay before plasma viremia rebounds post-therapy is suggestive of prolonged effects on the availability of CCR5 for virus entry (9). Measurements of CCR5 occupancy on PBMC after oral dosing of macaques with MVC support this view (1). In relation to the design of vaginal challenge studies, the lower vaginal fluid inhibitor concentrations in the DP-treated animals argue against using this challenge model. However, the alternative method, weekly challenges without DP use, requires most control animals to become infected during the 28-day period of ring use. Infection rates in vaginal challenge studies without DP use are highly variable (4, 5, 22), possible influences being the macaque sub-species (Indian vs. Chinese), the challenge stock and dose, and the use of antibiotics to eliminate vaginal flora (4, 5, 22). We are conducting studies to understand how best to challenge macaques that have vaginal rings inserted, and hence gain an understanding of the protective potential of this coitally-independent method of inhibitor delivery.

Overall, our results have implications for the use of DP in the macaque challenge model, at least in relation to the release and bio-distribution of ARVs from vaginal rings. Whether contraceptive hormones influence the thickness of the vaginal epithelium in women is more controversial. It is worth considering whether and how the performance of vaginal rings as ARV-delivery devices may vary during the natural menstrual cycle of women. For example, in response to fluctuating levels of steroid hormones, cervicovaginal fluid volumes increase significantly at the beginning of the fertile phase, peaking just before ovulation before decreasing again afterwards (8, 10). The thickness of the vaginal epithelium also changes significantly during the normal menstrual cycle. As these factors could affect the release and bio-distribution of ARVs from vaginal rings, some specific research on this topic is warranted.
ACKNOWLEDGEMENTS

This work was supported by the National Institute of Health (NIH, award U19 AI76982). We appreciate the donations of maraviroc and CMPD167 by ViiV Healthcare and the International Partnership for Microbicides, respectively. We thank Marty Springer for advice on the chemistry of CMPD167 and the provision of IC₅₀ values for maraviroc inhibition of chemokine binding.

CONTRIBUTIONS FROM AUTHORS

Malcolm, Veazey, Moore and Shattock are principal or primary co-investigators on the U19 grant, with responsibility for designing, coordinating and reporting all aspects of the work. Malcolm and Moore had lead responsibility for drafting the manuscript with contributions from all other authors. Fetherston, Major and Boyd performed vaginal ring manufacture, in vitro release testing and residual drug content extractions. Murphya and Fetherston completed physicochemical characterisation of the entry inhibitors (logP, water solubility, pKa). Klasse and Ketas performed in vitro antiviral efficacy experiments. Goldman and Geer performed all the bioanalytics associated with the macaque pharmacokinetic study (i.e., quantification of vaginal fluid, vaginal tissue, and plasma levels). Veazey, Doyle and Rasmussen were responsible for all aspects of the macaque handling and sampling.
REFERENCES


FIGURE LEGENDS

Fig. 1. *In vitro* mean daily release (+SD, n=4) versus time profiles for silicone elastomer matrix-type vaginal rings containing 400 mg of maraviroc or CMPD167. Simulated vaginal fluid was used as the release medium with complete replacement at all sampling timepoints (50 mL for days 1-3, 25 mL thereafter).

Fig. 2. Mean concentrations (+SD, n=6) of maraviroc and CMPD167 measured in the vaginal fluid (A and D), vaginal tissue (B and E) and blood plasma (C and F) of rhesus macaques during a 28-day period of continuous ring placement. Vaginal tissue and plasma samples were not recorded on Day 28 for CMPD167 rings. Note that the scales on the y-axes are not always the same for the two inhibitors.

Fig. 3. Calculated total mass of maraviroc and CMPD167 delivered to macaques (MAC+DEPO and MAC–DEPO) and released *in vitro* (calc) based on measurement of initial and residual drug contents performed by a solvent extraction method post-use. The ‘In vitro (ivrt)’ data set refers to the amount of each compound released based on the measured cumulative drug release from *in vitro* release testing (ivrt).
Table 1. Chemical structures, experimental physicochemical parameters and in vitro antiviral properties for CMPD167 and maraviroc.

<table>
<thead>
<tr>
<th>Microbicid</th>
<th>Chemical Structure</th>
<th>Physicochemical properties</th>
<th>EC&lt;sub&gt;50&lt;/sub&gt;[ng/mL] in PBMCs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maraviroc</td>
<td><img src="image" alt="Maraviroc Structure" /></td>
<td>M&lt;sub&gt;r&lt;/sub&gt;: 513.7 g/mol&lt;br&gt;MP: 197-198°C&lt;br&gt;Unbuffered water solubility: 1.03 ± 2.07 mg/mL&lt;br&gt;pK&lt;sub&gt;a&lt;/sub&gt;: 3.31 ± 3.05 (triazole), 7.84 ± 4.01 (tropane)&lt;br&gt;logP: 2.55 ± 0.04 (X), -0.32 ± 0.12 (XH&lt;sup&gt;+&lt;/sup&gt;)</td>
<td>SHIV-162P3  &lt;br&gt;Rhesus: 3.8 ± 5.6 (n=2) &lt;br&gt;Human: 0.69 ± 0.055 (n=2)</td>
</tr>
<tr>
<td>CMPD167</td>
<td><img src="image" alt="CMPD167 Structure" /></td>
<td>M&lt;sub&gt;r&lt;/sub&gt;: 574.4 g/mol&lt;br&gt;MP: 126.8°C&lt;br&gt;Unbuffered water solubility: 571.1 ± 7.3 µg/mL&lt;br&gt;pK&lt;sub&gt;a&lt;/sub&gt;: 2.35 ± 0.13 (-COOH), 7.84 ± 0.18 (base), 9.40 ± 0.04 (base)&lt;br&gt;logP: 2.66 ± 0.01 (X), 3.15 ± 0.01 (XH), 0.61 ± 0.04 (XH&lt;sup&gt;+&lt;/sup&gt;)</td>
<td>SHIV-162P3  &lt;br&gt;Rhesus: 0.14 ± 0.10 (n=5)  &lt;br&gt;Human: 0.09 ± 0.073 (n=5)</td>
</tr>
</tbody>
</table>

M<sub>r</sub> – relative molecular mass; MP – melting point; pK<sub>a</sub> – experimentally determined ionisation constants; logP – experimentally determined octanol-water partition coefficients; PBMCs - peripheral blood mononuclear cells
Table 2. CMPD167 and maraviroc concentration ratios within and between the various biological compartments as a function of Depo Provera or no-Depo Provera treatment. BP – blood plasma; VT – vaginal tissue; VF – vaginal fluid; DP – Depo Provera treatment; noDP – no Depo Provera treatment; n/a – ratio not available owing to zero value for one or more concentration parameter.

<table>
<thead>
<tr>
<th></th>
<th>Day 1</th>
<th>Day 7</th>
<th>Day 14</th>
<th>Day 28</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CMPD167</td>
<td>MRV</td>
<td>CMPD167</td>
<td>MRV</td>
</tr>
<tr>
<td></td>
<td>C167</td>
<td></td>
<td>C167</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DP:noDP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BP</td>
<td>noDP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VT</td>
<td>68.8</td>
<td>n/a</td>
<td>8.53</td>
<td>n/a</td>
</tr>
<tr>
<td>VF</td>
<td>0.777</td>
<td>0.0541</td>
<td>0.136</td>
<td>0.189</td>
</tr>
<tr>
<td>VF:VT</td>
<td>45.0</td>
<td>52.9</td>
<td>28.1</td>
<td>31.9</td>
</tr>
<tr>
<td>VF:BP</td>
<td>1.36 E4</td>
<td>7.94 E4</td>
<td>2.36 E4</td>
<td>4.49 E5</td>
</tr>
<tr>
<td>noDP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VF:VT</td>
<td>61.1</td>
<td>42.3</td>
<td>20.2</td>
<td>21.5</td>
</tr>
<tr>
<td>VF:BP</td>
<td>1.63 E6</td>
<td>n/a</td>
<td>1.06 E6</td>
<td>n/a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Fig. 2. Mean concentrations (+SE, n=6) of maraviroc and CMPD167 measured in the vaginal fluid (A and D), vaginal tissue (B and E) and blood plasma (C and F) of ferrets marques during a 28-day period of continuous ring placement. Vaginal tissue and plasma samples were not recorded on Day 28 for CMPD167 rings. Note that the scales on the y-axes are not always the same for the two inhibitors.